Market Place
Sourcing Support
ANI Pharmaceuticals` L-Glutamine Oral Powder Approved And Launched By FDA
15 Jul 2024 //
GLOBENEWSWIRE
Novitium Pharma`s Generic L-Glutamine Receives Approval in US
09 Jul 2024 //
FDA
Novitium`s Generic L Glutamine Receives Approval in the U.S.
10 Jan 2023 //
FDA
Enforcement Report - Week Of June 01, 2022
01 Jun 2022 //
FDA
Enforcement Report - Week of November 17, 2021
17 Nov 2021 //
FDA
Emmaus Life Sciences Partners with UpScript to Provide Telehealth Solutions
11 Nov 2021 //
PRNEWSWIRE
Enforcement Report - Week of December 18, 2019
18 Dec 2019 //
FDA
Emmaus Life Sciences Reinforces Positive Outcomes of Endari ® Clinical Trials
24 Sep 2019 //
BIOSPACE
Emmaus Announces Withdrawal of Marketing Authorization Application
19 Sep 2019 //
PR NEWSWIRE
EMA & FDA Historically Agree on Just About Every New Drug Approval
16 Aug 2019 //
RAPS
EMA’s CHMP Rejects Another Drug Approved by US FDA
01 Jul 2019 //
RAPS
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
EMA’s CHMP Offers Negative Opinion for Sickle Cell Drug Approved by US FDA
30 May 2019 //
RAPS
EMA’s CHMP Offers Negative Opinion for Sickle Cell Drug Approved by US FDA
30 May 2019 //
RAPS
Enforcement Report - Week of November 7, 2018
07 Nov 2018 //
FDA
Emmaus Life Sc with DMS Pharma to Provide Endari™ (L-glutamine oral powder)
30 Jul 2018 //
BUSINESSWIRE
Emmaus Life Sc Receives Validation From EMA for Sickle Cell`s Xyndari
12 Mar 2018 //
BUSINESS WIRE
Enforcement Report - Week of January 17, 2018
17 Jan 2018 //
FDA
Enforcement Report - Week of October 18, 2017
18 Oct 2017 //
FDA
FDA Approves First New Sickle Cell Drug in Almost 20 Years
07 Jul 2017 //
RAPS
Emmaus Receives Notice of Allowance for Japanese Patent for use of L-glutamine
07 Feb 2017 //
PR NEWSWIRE
Double-barreled? drug strategy cancels cancer`s backup plans
24 Jan 2017 //
NEWATLAS
Emmaus Receives Japanese Patent for use of L-glutamine
13 Dec 2016 //
PR NEWSWIRE
Emmaus` New Drug Application for Sickle Cell Disease Accepted for Review by FDA
08 Nov 2016 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.